

Amendments to the Claims

This listing of the claims will replace all prior versions, and listings, of the claims in the application.

Listing of Claims

1. (original) Process for preparing a solid pharmaceutical composition of perindopril or a salt thereof, comprising
 - (i) dry mixing of perindopril or a salt thereof with at least one inorganic carbonate, at least one carrier, and optionally other components, and
 - (ii) dry processing of the mixture obtained in step (i) to the desired solid form.
2. (original) Process according to claim 1, wherein the composition comprises the tert.-butyl amine salt of perindopril.
3. (currently amended) Process according to claim 1 ~~or 2~~, wherein the inorganic carbonate is selected from the group consisting of sodium carbonate, sodium hydrogen carbonate, magnesium carbonate, calcium carbonate or calcium hydrogen carbonate.
4. (currently amended) Process according to ~~any one of claims~~ claim 1 ~~to 3~~, wherein the molar ratio of perindopril or a salt thereof to inorganic carbonate is 1 to 0.1-0.9 and preferably 1 to 0.50-0.83.
5. (currently amended) Process according to ~~any one of claims~~ claim 1 ~~to 4~~, wherein the carrier is microcrystalline cellulose, lactose or a mixture thereof.

6. (original) Process according to claim 5, wherein the microcrystalline cellulose has a moisture content of 0.3 to 5.0% by weight, preferably 0.3 to 1.5% by weight.

7. (currently amended) Process according to claim 5 ~~or 6~~, wherein the lactose is anhydrous lactose.

8. (currently amended) Process according to ~~any one of claims~~ claim 1 to 7, wherein step (ii) is effected by direct compression of the mixture.

9. (currently amended) Process according to ~~any one of claims~~ claim 1 to 8, wherein the composition also comprises indapamide or a hydrate thereof.

10. (original) Process according to claim 9, wherein the hydrate is indapamide hemihydrate.

11. (currently amended) Process according to claim 9 ~~or 10~~, wherein 90% of the particles of indapamide or a hydrate thereof have a size of less than 80 μm .

12. (original) Process according to claim 11, wherein 90% of the particles of indapamide or a hydrate thereof have a size of less than 70 μm .

13. (original) Solid pharmaceutical composition of perindopril or a salt thereof, comprising

- (a) perindopril or a salt thereof,
- (b) at least one of microcrystalline cellulose having a moisture content of 0.3 to 5.0% by weight and anhydrous lactose,
- (c) optionally at least one inorganic carbonate, and

(d) optionally other components.

14. (original) Composition according to claim 13, wherein the molar ratio of perindopril or a salt thereof to inorganic carbonate is 1 to 0.1-0.9 and preferably 1 to 0.50-0.83.

15. (currently amended) Composition according to claim 13 ~~or 14~~, wherein the microcrystalline cellulose has a moisture content of 0.3 to 1.5% by weight.

16. (original) Composition according to claim 15 which further comprises indapamide or a hydrate thereof.

17. (original) Composition according to claim 16, wherein 90% by volume of the particles of indapamide or a hydrate thereof have a size of less than 80 μm .